Persones / Equip Humà

Héctor Salvador Hernández

Buscador de publicacions

Publicacions

  • Ortega-Bertran S, Fernández-Rodríguez J, Magallón-Lorenz M, Zhang X, Creus-Bachiller E, Diazgranados AP, Uriarte-Arrazola I, Mazuelas H, Blanco I, Valverde C, Carrió M, Villanueva A, De Raedt T, Romagosa C, Gel B, Salvador-Hernandez H, Ferrer M, Lázaro C and Serra E.

    Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models

    CLINICAL CANCER RESEARCH . 31(5): 907-920.

    [doi:10.1158/1078-0432.CCR-24-2807]

  • Camiña-Conforto G, Ivars M, Sarquella-Brugada G, Carlos Valera Dávila, Salvador-Hernandez H, Rovira-Zurriaga C and Baselga E.

    Phacomatosis pigmentokeratotica: Exploring extracutaneous comorbidities and topical therapy

    PEDIATRIC DERMATOLOGY . 41(5): 904-907.

    [doi:10.1111/pde.15632]

  • Azizi, AA, Hargrave, D, Passos, J, Wolkenstein, P, Rosenbaum, T, Santoro, C, Rosenmayr, V, Pletschko, T, Ascierto, PA and Salvador-Hernandez H.

    Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

    Neuro-Oncology Practice . 11(5): 515-531. Nº de cites: 2

    [doi:10.1093/nop/npae038]

  • Fresno Cañada C, Gispets Parcerisas J, Del Prado-Sanchez C, Puigventós E, Pérez-Jaume S, Salvador-Hernandez H, Llorca Cardeñosa A and Prat-Bartomeu J.

    DRI Triton SS-OCT applied to detect choroidal nodules in paediatric patients affected by NF1

    Heliyon . 10(8): . Nº de cites: 1

    [doi:10.1016/j.heliyon.2024.e29263]

  • Pinto EM, Fridman C, Figueiredo BC, Salvador-Hernandez H, Teixeira MR, Pinto C, Pinheiro M, Kratz CP, Lavarino C, Legal EAMF, Le A, Kelly G, Koeppe E, Stoffel EM, Breen K, Hahner S, Heinze B, Techavichit P, Krause A, Ogata T, Fujisawa Y, Walsh MF, Rana HQ, Maxwell KN, Garber JE, Rodriguez-Galindo C, Ribeiro RC and Zambetti GP.

    Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility

    Human Genetics and Genomics Advances . 5(1): 100244-100244. Nº de cites: 4

    [doi:10.1016/j.xhgg.2023.100244]

  • Viskochil, D, Wysocki, M, Learoyd, M, Sun, P, So, KR, Evans, A, Lai, FC and Salvador-Hernandez H.

    Effect of food on selumetinib pharmacokinetics and gastrointestinal tolerability in adolescents with neurofibromatosis type 1-related plexiform neurofibromas

    neuro-oncology advances . 6(1): . Nº de cites: 2

    [doi:10.1093/noajnl/vdae036]

  • Simao-Rafael M, Cruz-Martínez O, Pérez-Jaume S, Santa-María López V, Lavarino C, Salvador-Hernandez H, Muchart-Lopez J, Hinojosa J, Suñol M and Morales-La Madrid A.

    Use of bevacizumab in pediatric low-grade glioma: Ten-year experience in a single center

    EJC Paediatric Oncology . 2: 100115.

    [doi:10.1016/j.ejcped.2023.100115]

  • Carton, C, Evans, DG, Blanco, I, Friedrich, RE, Ferner, RE, Farschtschi, S, Salvador-Hernandez H, Azizi, AA, Mautner, V, Rohl, C, Peltonen, S, Stivaros, S, Legius, E and Oostenbrink, R.

    ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1

    EClinicalMedicine . 56: . Nº de cites: 43

    [doi:10.1016/j.eclinm.2022.101818]

  • Parada-Avendaño I, Salvador-Hernandez H, García RG, Martorell-Sampol L, García-Fontecha CG, Torner-Rubies F and Pérez-López LM.

    Lateralized overgrowth as a guiding sign of abdominal neoplasms for pediatric orthopedic surgeons

    Joint Diseases and Related Surgery . 34(1): 3-8. Nº de cites: 1

    [doi:10.52312/jdrs.2023.903]

  • Catasús N, Rosas I, Bonache S, Negro A, Torres-Martin M, Plana-Pla A, Salvador-Hernandez H, Serra E, Blanco I and Castellanos E.

    Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype in vitro

    MOLECULAR THERAPY NUCLEIC ACIDS . 30: 493-505. Nº de cites: 5

    [doi:10.1016/j.omtn.2022.10.026]